Community-acquired pneumonia and acid-suppressive drugs: position statement

about

Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

P2860

Q22241389-B23A79D6-3F47-4F16-B26F-13093C20F8AB Q33893627-A29D61C5-170E-4529-864D-0D6230E93826

P2860

Community-acquired pneumonia and acid-suppressive drugs: position statement

Item

http://www.wikidata.org/entity/Q36398145

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Community-acquired pneumonia and acid-suppressive drugs: position statement

@ast

Community-acquired pneumonia and acid-suppressive drugs: position statement

@en

type

Item

label

Community-acquired pneumonia and acid-suppressive drugs: position statement

@ast

Community-acquired pneumonia and acid-suppressive drugs: position statement

@en

prefLabel

Community-acquired pneumonia and acid-suppressive drugs: position statement

@ast

Community-acquired pneumonia and acid-suppressive drugs: position statement

@en

P1476

Community-acquired pneumonia and acid-suppressive drugs: position statement

@en

P2093

CAG Clinical Affairs Committee

http://www.w3.org/2001/XMLSchema#string

P2860

Proton pump inhibitor treatment for acute peptic ulcer bleeding

Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.

Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.

Prevention of chronic NSAID induced upper gastrointestinal toxicity.

Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough.

U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

P304

119-21, 123-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16482239

http://www.w3.org/2001/XMLSchema#string

P921

Bruschtfiewer

P932

2538974

http://www.w3.org/2001/XMLSchema#string

Community-acquired pneumonia and acid-suppressive drugs: position statement

about

P2860

P2860

Community-acquired pneumonia and acid-suppressive drugs: position statement

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P433

P478

P577

P698

P921

P932